A safe, well-tolerated, and effective treatment for metastatic esophageal cancer
Researchers found that oxaliplatin combined with capecitabine provided a safe, well-tolerated, and effective treatment for patients with metastatic esophageal squamous cell cancer. The combination showed significant clinical benefits, including partial responses in 43.8% of patients and a median overall survival of 10.0 months.